H.C. Wainwright analyst Swayampakula Ramakanth downgraded Oncorus to Neutral from Buy without a price target. ONCR-177 failed to deliver in solid tumors, Ramakanth tells investors in a research note. The analyst removed all revenues associated with ONCR-177 from the model and as a result, moved to the sidelines "for now."
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ONCR:
- Oncorus downgraded to Neutral from Buy at Chardan
- Piper downgrades Oncorus with plug pulled on lead program
- Oncorus downgraded to Neutral from Overweight at Piper Sandler
- Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
- Oncorus announces reprioritization of lead product candidate ONCR-021